SCHEMBL1339132

SCHEMBL1339132

Cn1c(=O)c(-c2ccc(Br)cc2)cc2c3ccccc3n(C)c21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 2/20 0.46
▸ ACHE P22303 2/20 0.42
▸ BCHE P06276 1/20 0.42
▸ GPR3 P46089 1/20 0.41
▸ KMT2A Q03164 3/20 0.40
▸ GAA P10253 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ RXFP1 Q9HBX9 2/20 0.40
▸ HPGD P15428 1/20 0.39
▸ HSP90AA1 P07900 1/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ NQO2 P16083 1/20 0.39
▸ LMNA P02545 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ CDK4 P11802 1/20 0.38
▸ CCND1 P24385 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337392 0.86 HSD17B10 (0.46) HSD17B10ACHEBCHEGPR3KMT2A
SCHEMBL1336997 0.86 MAPK14 (0.49) HSD17B10GPR3KMT2AMEN1RXFP1
SCHEMBL3867031 0.84 KDM4E (0.51) HSD17B10ACHEBCHEKMT2AGAA
SCHEMBL1338146 0.80 MEN1 (0.39) HSD17B10KMT2AGAAMEN1HPGD
SCHEMBL3135467 0.79 KMT2A (0.39) HSD17B10KMT2AGAAMEN1RXFP1
SCHEMBL3135471 0.79 KMT2A (0.36) HSD17B10KMT2AGAAMEN1RXFP1
SCHEMBL1339086 0.79 L3MBTL1 (0.42) RXFP1SMN1; SMN2MAPTALDH1A1POLB
SCHEMBL4760636 0.78 RXFP1 (0.37) KMT2AGAAMEN1RXFP1HSP90AA1
SCHEMBL1339068 0.78 MEN1 (0.36) HSD17B10KMT2AGAAMEN1RXFP1
SCHEMBL1338964 0.77 GSK3B (0.41) KMT2AGAAMEN1KDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 HSD17B10 445/4885ACHE 455/4885BCHE 1902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback